Food from CO2

Arkeon Biotechnologies, a Viennese startup, uses gas fermentation technology to convert CO2 into food products

25-Mar-2022 - Vienna-based startup Arkeon Biotechnologies has closed its seed funding in an oversubscribed investment round of more than $7 million. Arkeon is the world's first company to use gas fermentation technology from archaea, a microorganism with unique properties, for food applications. The ...

Green chemistry needs more green toxicology

Sustainable bioeconomy: Development of environmentally friendly bio-shampoos and plant protection agent technologies

16-Feb-2022 - With the early assessment of sustainable, newly developed chemicals and products it is possible to assess a potential risk of toxic substances being released at a later point in product cascades. This has been revealed in a proof-of-concept study jointly coordinated by Goethe University Frankfurt ...

Lab-on-chip systems: From prototype to series production in no time

Globally unique solution saves time and costs

31-Jan-2022 - It is used millions of times a day all over the world: as a portable miniature laboratory, the Corona antigen rapid test is currently clearly demonstrating the potential of lab-on-chip systems. Analysis within a very short time is of immense importance, especially during a pandemic. Ever more of ...

Deep learning, prefabricated

09-Oct-2019 - Self-driving cars, the automatic detection of cancer cells, online translation: deep learning makes it all possible. The ETH spin-off Mirage Technologies has developed a deep learning platform that aims to help start-ups and companies more quickly develop and optimise their products. The name has ...

Catalent Invests $7.3 Million in Italy

Expands Softgel Encapsulation and Packaging Capabilities in Support of Consumer Health

08-Oct-2018 - Catalent Pharma Solutions announced that it had completed the first phase of a $7.3 million investment to upgrade and expand its packaging and softgel encapsulation capabilities at its facility in Aprilia, Italy. The first phase of investment, completed in August 2018, saw the expansion and ...

Sun Pharma & Moebius Medical sign exclusive global licensing deal

Dela contains development of novel liposomal non-opiod pain product for osteoarthritis

13-Dec-2016 - Sun Pharma and Israel-based Moebius Medical have entered into an exclusive worldwide licensing deal to further develop MM-II, a novel pharmaceutical candidate for the treatment of pain in osteoarthritis. MM-II is a novel non-opioid product that leverages the physical properties of proprietary ...

Lonza holds grand opening for state-of-the-art drug product services lab

04-Nov-2016 - Lonza held the grand opening today of its state-of-the-art pharmaceutical Drug Product Services laboratories in the Stücki Science Park Basel (CH). Scientists in the new 1300 m2 facility will focus initially on formulation development, drug product analytical development and quality ...

Technology that miniaturises measuring devices

14-May-2014 - VTT Technical Research Centre of Finland has developed smart optical measuring devices with companies for uses that include optimisation of vehicle engines, reduction and monitoring of environmental emissions, and quality control of pharmaceuticals. The FABRY research project aimed at utilisation ...

The science of collaboration

The future of biomedical innovation depends in part on a new trend for all players in biomedical innovation to work together for the common goal

30-Aug-2013 - It's a long, expensive, risky road to turn a scientific breakthrough into a treatment that can help patients. Fewer organizations are trying to tackle the challenges alone, says a new paper from MIT researchers published in the journal Science Translational Medicine. An essential new way to move ...

Frost & Sullivan: Proposed regulatory uniformity to boost venture capital investments in healthcare arena

Venture capital funding to focus on enhanced drug delivery and product life cycle management technologies

25-Jan-2013 - In a shaky economic climate, where fund raising has become tight and there are decreasing opportunities to exit the market, venture capital (VC) firms have become extremely cautious in choosing their investments. This has lead to the trend of low value deals. However, segments like healthcare ...